Sebastian Gensior

A comprehensive analysis of AI-powered healthcare innovations, regulatory shifts, strategic partnerships, and emerging technologies reshaping medicine and wellness

CPP Investments has deployed over $4 billion in life sciences since 2017—from Keytruda royalties to BridgeBio synthetics to biotech venture. How Canada's largest pension fund built a pharma powerhouse through patient capital and creative deal structures.

Introduction and Company Overview Founded in 1998, Gan & Lee Pharmaceuticals (SHSE: 603087) is a Chinese biopharma company specializing in insulin analogues and related medical devices. Headquartered in Beijing with an industrial park of ~200,000 m², Gan & Lee has grown to over 5,500 employees globally. The company

Taiwan's biotech industry reached record output in 2025 as the island leverages semiconductor-era manufacturing expertise to build Asia's next pharmaceutical hub. This analysis examines the companies, regulatory frameworks, CDMO expansion, and investment ecosystem shaping the sector's trajectory.

Pharmaceutical mergers and acquisitions face unprecedented antitrust scrutiny in the United States and European Union. Regulators no longer focus solely on obvious horizontal overlaps where merging firms sell competing drugs but also examine vertical foreclosure risks and pipeline competition—overlaps between marketed drugs and another company's pipeline candidates,

Clinical trial liability insurance represents a critical but often underestimated cost in drug development. The global clinical trials market reached approximately $76.7–87 billion in 2024 and is projected to grow at 5.2–6.3% CAGR through 2034, driving parallel expansion in the insurance sector. Understanding the complex

Biotech deal activity surges in year-end 2025 window The final week of 2025 and opening days of 2026 delivered over $15 billion in announced and closed transactions across the biotech and healthcare spectrum. Royalty Pharma completed its $300 million acquisition of remaining Evrysdi royalties on December 29, while several

Sublicense royalties have become an important feature in pharmaceutical royalty financing deals, especially as biotech firms and pharma companies seek creative funding structures. In simple terms, a sublicense royalty (or sublicensing income) is the share of revenue that an original licensor earns when its licensee grants a sub-license to

In the basement of a nondescript office building in South San Francisco, the fluorescent lights still hummed over empty lab benches. Three months earlier, this space had buzzed with scientists racing to prove that their CAR-T therapy could cure cancer. Now, the centrifuges sat silent, the freezers unplugged, and

Six thoughtful (and slightly cheeky) resolutions for biotech investors, executives, and scientists to make 2026 a breakthrough year.